Ticagrelor Therapy for RefrACTORy Migraine - Pilot Study
Sponsor: |
AstraZeneca |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAO4109 |
U.S. Govt. ID: |
NCT02518464 |
Contact: |
Robert Sommer: 212-342-0886 / rs2463@cumc.columbia.edu |
This study is for patients who have severe migraine headaches that might be a result of a hole in the heart wall called a Patent Foreman Ovale, or PFO. It is known that as many as 40% of patients with migraine headaches also have a PFO. It is not well understood how the two are related, or how having a hole in the heart wall could cause headaches. In this study, we will test a drug, called ticagrelor (Brilanta), which is FDA approved for patients who have had heart attacks and are found to have blockages in their coronary arteries, but has never been tested as a treatment for migraines.
This study is closed
Investigator
Robert Sommer, MD
Have you had migraines for at least one year? |
Yes |
No |
Do you suffer at least 6 headache days per month? |
Yes |
No |
Do you live in the New York metro area or are willing to travel for appointments? |
Yes |
No |
Are you taking daily blood thinning medication? |
Yes |
No |